← Eichor
Condition: Transition Cell Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Transition Cell Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Is the Normal Looking Bladder Mucosa on WL Cystoscopy During TURBT Really Normal and Can NBI Detect Hidden Tumor
Phase N/A · 2 location(s) · Armed Forces Institute of Urology, Rawalpindi · NCT06729346The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients
NA · 1 location(s) · Nationwide Children's Hospital · NCT07718204FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Phase 1/Phase 2 · 19 location(s) · Pierre Fabre Medicament · NCT06669117HEalth Advocate for Liver Transplantation: Improving Transition of Care for Adolescent Liver Transplant Recipients
NA · 2 location(s) · University of California, San Francisco · NCT06386198A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Phase 2/Phase 3 · 2 location(s) · Hansoh BioMedical R&D Company · NCT06417008Understanding the Transition from Normal Melanocytes to Nevus to Melanoma
Phase N/A · 2 location(s) · Fundacion Clinic per a la Recerca Biomédica · NCT06605417A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cel
Phase 1/Phase 2 · 40 location(s) · Regeneron Pharmaceuticals · NCT04077099
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.